Phreesia (PHR)
(Delayed Data from NYSE)
$21.19 USD
-1.59 (-6.98%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $21.20 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.19 USD
-1.59 (-6.98%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $21.20 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Zacks News
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -87.50% and 4.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nyxoah (NYXH) delivered earnings and revenue surprises of -2.22% and 56.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Phreesia (PHR) Could Surge 27.77%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Phreesia (PHR) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
Here's Why Phreesia (PHR) is Poised for a Turnaround After Losing -18.25% in 4 Weeks
by Zacks Equity Research
Phreesia (PHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Compared to Estimates, Phreesia (PHR) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended April 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 31.37% and 0.20%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q1 Potential of Phreesia (PHR): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Phreesia (PHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2024.
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace (TALK) delivered earnings and revenue surprises of 50% and 2.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Stock Market News for Mar 18, 2024
by Zacks Equity Research
Wall Street closed lwer on Friday with the Fed facing an inflation dilemma ahead of the policy meeting.
Phreesia (PHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended January 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 3.45% and 2.01%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Phreesia (PHR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 27.27% and 4.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull Of The Day: Phreesia (PHR)
by Brian Bolan
This company has accelerated its push to profitability and that will bring in a whole new set of investors
Phreesia and LCI have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Phreesia and LCI have been highlighted as Zacks Bull and Bear of the Day.
New Strong Buy Stocks for January 29th
by Zacks Equity Research
PHR, SASR, QCRH, WDC and NU have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2023.
Best Momentum Stocks to Buy for January 11th
by Zacks Equity Research
ADMA, ARQT and PHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.
New Strong Buy Stocks for January 11th
by Zacks Equity Research
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
Does Phreesia (PHR) Have the Potential to Rally 30.09% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Phreesia (PHR) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 77.77% Upside in Phreesia (PHR): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Phreesia (PHR) points to a 77.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.